- Conditions
- Prostate Cancer
- Interventions
- lapatinib ditosylate
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 17,247
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CXA-10
- Drug
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- ABI-1179, ABI-1179 Placebo
- Drug
- Lead sponsor
- Assembly Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Kansas City, Missouri • Rochester, New York • Seattle, Washington
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- azacitidine, lenalidomide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adult Lymphoblastic Lymphoma
- Interventions
- Fludarabine, Total Body Irradiation
- Drug · Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prostate Cancer
- Interventions
- CEP-701
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- High-risk Diffuse Large B-cell Lymphoma
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more
- Conditions
- Prostate Cancer
- Interventions
- ET 743
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
- Interventions
- Adalimumab Injection [Humira], Saline Solution for Injection
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 9
- States / cities
- Duarte, California • Palo Alto, California • Sacramento, California + 4 more
- Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
- Interventions
- BB-1701
- Drug
- Lead sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- San Francisco, California • Nashville, Tennessee • Fairfax, Virginia
- Conditions
- Celiac Disease
- Interventions
- Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
- Drug · Other
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
- Conditions
- Multiple Myeloma
- Interventions
- Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 12
- States / cities
- Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more
- Conditions
- Staphylococcus Aureus Pneumonia
- Interventions
- MEDI4893, Placebo
- Drug · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Detroit, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 17
- States / cities
- Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more
- Conditions
- Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
- Interventions
- Homoharringtonine, Imatinib Mesylate
- Drug
- Lead sponsor
- ChemGenex Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Entinostat, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Roberto Pili
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana
- Conditions
- Graves' Disease
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Glendale, Arizona • Los Angeles, California • Doral, Florida + 7 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Cetuximab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 8
- States / cities
- Aventura, Florida • Miami Beach, Florida • Chicago, Illinois + 4 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
- Conditions
- Dry Eye
- Interventions
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 26
- States / cities
- Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
- Conditions
- Hodgkin Disease
- Interventions
- Nivolumab, brentuximab vedotin, bendamustine
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more